1. Exploiting Tumor Necrosis Factor Aberrations in Marginal Zone Lymphoma.
- Author
-
Miller, Ryan M., Perciavalle, Matthew A., Mason, Emily F., Yelvington, Bradley J., and Reddy, Nishitha M.
- Subjects
- *
MUCOSA-associated lymphoid tissue lymphoma , *TUMOR necrosis factors , *DIFFUSE large B-cell lymphomas , *THERAPEUTICS , *B cell lymphoma , *PHYSICIANS - Abstract
The canonical pathway is rapid, transient, and involves immune and inflammatory responses, whereas the noncanonical pathway is a slower, sustained response that often controls developmental processes including B-cell maturation.[7],[8] Deregulation of the NF- B pathway has been described in a variety of B-cell malignancies, including Hodgkin lymphoma, MALT lymphoma, diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and multiple myeloma. On initial workup, a positron emission tomography (PET) and/or computed tomography (CT) showed a large left paraspinal pelvic mass and a left supragluteal mass with moderate fludeoxyglucose (FDG) uptake. Marginal zone lymphoma (MZL) is a heterogenous group of low-grade B-cell lymphomas that harbor various genetic alterations. Case 2 The patient was a 67-year-old female who underwent biopsy of an eyelid lesion (Figs 3A-C), which showed a dense infiltrate of B lymphocytes and plasma cells, and was diagnosed with ocular extranodal MZL of mucosa-associated lymphoid tissue (MALT lymphoma). [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF